TOAK yields 6.99% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 10
Combined, TOAK + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TOAK + PFE for your $10,000?
TOAK seeks to provide capital appreciation, with reduced price volatility. The portfolio is actively managed and traded, using defined risk options with a short duration of zero to one year. Define risk options are those in which the maximum loss for any option during the expiry period is no more than the premium invested. An option position pairing strategy is employed to reduce risk. The fund does not use leverage or naked option writing. However, option contracts may be exchanged-listed, over-the-counter (OTC), or FLEX options. The use of OTC options exposes investors to counter-party risk. Based on the portfolio managers assessment of current economic and market conditions, along with existing holdings, the fund may invest in long calls, long puts, debit spreads or a combination of these strategies. In choosing positions for the portfolio, TOAK managers consider price, liquidity, duration, and risk into consideration.
Full TOAK Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.